Advance Search

SMASH: An initiative for equitable access to precision medicine for rare or severe lipid disorders

SMASH: A global initiative for lipid disorders

Miriam Larouche
Université de Montréal, Departement of Medicine, Montreal, Canada and ECOGENE-21 Clinical Trial Center, Chicoutimi, Canada
Marianne Abifadel
Laboratory of Biochemistry and Molecular Therapeutics (LBTM), Faculty of Pharmacy, Pôle Technologie- Santé, Saint Joseph University of Beirut, Beirut, Lebanon
Alberico L. Catapano
IRCCS Multimedica, Milano, Italy and University of Milan, Italy
Marina Cuchel
Division of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia, USA
Raul D. Santos
ipid Clinic Heart Institute (InCor) University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil and Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil
Frederick J. Raal
University of the Witwatersrand, Division of Endocrinology and Metabolism, Faculty of Health Sciences, Johannesburg, South Africa
Daniel Gaudet
Université de Montréal, Departement of Medicine, Montreal, Canada and ECOGENE-21 Clinical Trial Center, Chicoutimi, Canada
Keywords:
Copyright and Licensing:

Copyright (c) 2024 European Atherosclerosis Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Abstract

Background. Despite significant improvements in our knowledge of the biological basis of rare or severe lipid disorders and the refinement of their clinical management, equity challenges and barriers to access are gradually emerging, particularly in low-middle-income countries or remote regions. SMASH (System and Molecular Approaches of Severe Hyperlipidemia) is a global initiative with the goal of making precision medicine innovations available without discrimination for patients affected by rare or severe lipid disorders.
Objectives. SMASH main objective is to facilitate access to accurate diagnosis and optimal treatment for patients affected by rare or severe lipid disorders regardless of where they live, their gender, ethnicity, or socioeconomic status.
Overview. SMASH is an international initiative comprising five interrelated components: SMASH-Access, -Natural History, -Trials, -e-Share, and -Biorepository. SMASH has selected as templates four severe lipid disorders that have in common the accelerated development of precise diagnosis and the emergence of innovative treatments that represent equity challenges: HoFH (homozygous familial hypercholesterolemia), persistent chylomicronemia, LCAT (lecithin-cholesterol acyl transferase) deficiency, and severely elevated Lp(a). Access issues are broad and not limited to clinical or socio-economic factors. Several environmental variables are also contributory. 
Summary. SMASH is developed to conceive, support, or catalyze initiatives that might improve our understanding of rare or severe dyslipidemias and facilitate access to innovation for those affected. It will not duplicate ongoing initiatives but will support them. A system approach and a structured collaborative effort is mandatory to provide fair access to emerging treatments to patients in both developed countries and emerging economies.

PDF
PDF

Article Metrics Graph

Article Views | PDF Downloads
Chart Graph | Range Graph

References

  1. Hegele RA, Boren J, Ginsberg HN, et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol 2020; 8:50-67. https://doi.org/10.1016/S2213-8587(19)30264-5
  2. Mansfield BS, Mohamed F, Larouche M, Raal FJ. The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias. J Clin Med 2024; 13. https://doi.org/10.3390/jcm13144160
  3. Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J 2023; 44:2277-91. https://doi.org/10.1093/eurheartj/ehad197
  4. Spagnuolo CM, Wang J, McIntyre AD, et al. Comparison of patients with familial chylomicronemia syndrome and multifactorial chylomicronemia syndrome. J Clin Endocrinol Metab 2024. https://doi.org/10.1210/clinem/dgae613
  5. Vitali C, Rader DJ, Cuchel M. Novel therapeutic opportunities for familial lecithin:cholesterol acyltransferase deficiency: promises and challenges. Curr Opin Lipidol 2023; 34:35-43. https://doi.org/10.1097/MOL.0000000000000864
  6. Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol 2024; 18:e308-e19. https://doi.org/10.1016/j.jacl.2024.03.001
  7. Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2022; 16:e77-e95. https://doi.org/10.1016/j.jacl.2022.08.007
  8. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008; 117:176-84. https://doi.org/10.1161/CIRCULATIONAHA.107.715698
  9. Stock JK. Homozygous Familial Hypercholesterolaemia International Clinical Collaboration (HICC) registry: Levelling up access to treatment urgently needed. Atherosclerosis 2022; 346:84-5. https://doi.org/10.1016/j.atherosclerosis.2022.02.008
  10. Raal FJ, Rosenson RS, Reeskamp LF, et al. The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia. JACC Adv 2023; 2:100648. https://doi.org/10.1016/j.jacadv.2023.100648
  11. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356:148-56. https://doi.org/10.1056/NEJMoa061189
  12. Gaudet D, Greber-Platzer S, Reeskamp LF, et al. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J 2024; 45:2422-34. https://doi.org/10.1093/eurheartj/ehae325
  13. Gu J, Gupta RN, Cheng H, et al. Current treatments for the management of homozygous familial hypercholesterolemia: a systematic review and commentary. Eur J Prev Cardiol 2024. https://doi.org/10.1093/eurjpc/zwae144
  14. Brisson D, Larouche M, Chebli J, et al. Correlation between chylomicronemia diagnosis scores and post-heparin lipoprotein lipase activity. Clin Biochem 2023; 114:67-72. https://doi.org/10.1016/j.clinbiochem.2023.02.002
  15. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". Atherosclerosis 2018; 275:265-72. https://doi.org/10.1016/j.atherosclerosis.2018.06.814
  16. Watts GF, Rosenson RS, Hegele RA, et al. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. N Engl J Med 2024. https://doi.org/10.1056/NEJMoa2409368
  17. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. N Engl J Med 2024; 390:1781-92. https://doi.org/10.1056/NEJMoa2400201
  18. Yang K, Wang J, Xiang H, et al. LCAT- targeted therapies: Progress, failures and future. Biomed Pharmacother 2022; 147:112677. https://doi.org/10.1016/j.biopha.2022.112677
  19. Vitali C, Bajaj A, Nguyen C, et al. A systematic review of the natural history and biomarkers of primary lecithin:cholesterol acyltransferase deficiency. J Lipid Res 2022; 63:100169. https://doi.org/10.1016/j.jlr.2022.100169
  20. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102:1082-5. https://doi.org/10.1161/01.cir.102.10.1082
  21. Zafrir B, Aker A, Saliba W. Extreme lipoprotein(a) in clinical practice: A cross sectional study. Int J Cardiol Cardiovasc Risk Prev 2023; 16:200173. https://doi.org/10.1016/j.ijcrp.2023.200173
  22. Schwartz GG, Ballantyne CM. Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis 2022; 349:110-22. https://doi.org/10.1016/j.atherosclerosis.2022.04.020
  23. O'Donoghue ML, Rosenson RS, Gencer B, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med 2022; 387:1855-64. https://doi.org/10.1056/NEJMoa2211023
  24. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med 2020; 382:244-55. https://doi.org/10.1056/NEJMoa1905239
  25. Nissen SE, Wolski K, Balog C, et al. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. JAMA 2022; 327:1679-87. https://doi.org/10.1001/jama.2022.5050
  26. Nicholls SJ, Nissen SE, Fleming C, et al. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. JAMA 2023; 330:1042-53. https://doi.org/10.1001/jama.2023.16503
  27. Nissen SE, Linnebjerg H, Shen X, et al. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial. JAMA 2023; 330:2075-83. https://doi.org/10.1001/jama.2023.21835
  28. Baker DW. Achieving Health Care Equity Requires a Systems Approach. Jt Comm J Qual Patient Saf 2024; 50:1-5. https://doi.org/10.1016/j.jcjq.2023.10.018

Send mail to Author

Send Cancel

Custom technologies based on your needs

  • MongoDB
  • ElasticSearch
  • Redis
  • Solr
  • Memcached